FDA Modernization Act
The most significant legislative development for laboratory beagles in decades. It removes the legal floor that required their use. But removing a floor is not the same as changing practice.
The 1938 Mandate
The original Federal Food, Drug, and Cosmetic Act of 1938 was itself a response to tragedy. The sulfanilamide disaster of 1937 — in which an untested toxic solvent in a liquid antibiotic killed 107 people, many of them children — prompted Congress to require that drugs be tested for safety before marketing.
For 84 years, this requirement was interpreted to mandate animal testing. No new drug could reach human clinical trials without first being tested in at least 2 animal species: 1 rodent and 1 non-rodent. The beagle became the standard non-rodent. The 1938 law did not name the beagle. It did not need to — regulatory custom and ICH guidelines filled in the specifics.
Modernization Act 2.0 (December 2022)
Amended the Federal Food, Drug, and Cosmetic Act to state that drug sponsors may use "nonclinical tests or studies" — a term explicitly defined to include cell-based assays, organ chips, computer models, and other non-animal methods — instead of animal studies.
Sponsors are no longer legally required to conduct animal studies. They may choose to do so, and many will, but the statutory obligation is gone.
This distinction is critical. The law permits alternatives; it does not prohibit animal studies. Pharmaceutical companies remain free to test on beagles if they choose.
The FDA retains discretion to request animal data if it deems non-animal evidence insufficient. In practice, FDA reviewers accustomed to animal data continue to expect it.
Modernization Act 3.0 (December 2025)
Passed the United States Senate unanimously — a rare signal of broad bipartisan support. Builds on 2.0 by:
Requiring the agency to produce formal guidance documents specifying how non-animal methods can satisfy regulatory requirements.
Setting deadlines for FDA to issue guidance and report on progress toward reducing animal testing.
Addressing not just new drugs but also biologics, biosimilars, and certain device applications.
House passage and presidential signature remain required. The legislative trajectory suggests eventual enactment, but the timeline is uncertain.
The FDA Phase-Out Plan (April 2025)
The FDA announced a concrete phase-out plan for certain animal testing requirements:
mAbs are large-molecule biologics with well-understood mechanisms. The FDA determined that for many mAbs, animal toxicology studies provide limited predictive value because the drugs are human-specific — they often do not bind to the target in animal species.
Sequential reduction of animal testing requirements across drug classes, prioritizing those where non-animal alternatives are most mature.
The phase-out plan sets directions, not deadlines. Individual drug applications will be evaluated on a case-by-case basis.
Why Practical Impact Is Slow
The gap between legal permission and practical change is wide. Several forces maintain the status quo:
FDA reviewers evaluate drugs based on safety. The burden of proof for any change falls on the sponsor. Demonstrating that a non-animal method is "adequate and well-controlled" requires validation data still being generated.
The International Council for Harmonisation guidelines (M3, S7A, S7B, S9) are adopted by the US, EU, and Japan. These guidelines specify animal studies. Changing them requires international consensus, which moves slowly.
Pharmaceutical companies have established workflows, CRO contracts, and internal expertise built around animal testing. Switching to unfamiliar methods introduces uncertainty and perceived risk.
If a drug harms patients after being approved based on non-animal data, the sponsor faces potential litigation. The legal and reputational risk of being first to abandon animal testing discourages early movers.
Despite documented limitations, dog telemetry data remains expected for most small-molecule drugs. The CiPA initiative offers a potential replacement, but full regulatory acceptance is years away.